A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma Read more
An Open-Label, Dose Escalation And Dose Expansion Trial Evaluating The Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of Orally Administered CA-4948 In Patients With Relapsed Or Refractory Hematologic Malignancies Read more
A Phase 1b/2, Open-Label Trial To Assess The Safety And Preliminary Efficacy Of Epcoritamab (GEN3013; Duobody®-CD3xCD20) In Combination With Other Agents In Subjects With B-Cell Non-Hodgkin Lymphoma Read more
A Phase 1, Multicenter, Open-Label Study Of Bms-986403 In Subjects With Relapsed And/Or Refractory Chronic Lymphocytic Leukemia (Cll) Or Small Lymphocytic Lymphoma (Sll) Read more
A Phase 1b/2, Open-Label, Safety And Efficacy Study Of Epcoritamab (GEN3013; Duobody®-CD3 X CD20) In Relapsed/Refractory Chronic Lymphocytic Leukemia Read more
Long-Term Follow-Up Study For Participants Of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells Read more
